Want to see ARVN full AI Analyst Report?
ARVN Stock Chart & Stats
$9.60
-$0.09(-1.11%)
At close: 4:00 PM EDT
$9.60
-$0.09(-1.11%)
Day’s Range― - ―
52-Week Range$6.74 - $14.51
Previous Close$8.04
Volume385.67K
Average Volume (3M)842.89K
Market Cap
$474.70M
Enterprise Value-$13.73M
Total Cash (Recent Filing)$567.90M
Total Debt (Recent Filing)$8.20M
Price to Earnings (P/E)40.3
Beta1.38
Next Earnings
Nov 10, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding65,386,190
10 Day Avg. Volume713,927
30 Day Avg. Volume842,895
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.77
Price to Sales (P/S)2.93
P/FCF Ratio-2.79
Enterprise Value/Market Cap-0.03
Enterprise Value/Revenue-0.04
Enterprise Value/Gross Profit-0.04
Enterprise Value/Ebitda-3.52
Forecast
1Y Price Target
$15.07Price Target Upside56.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$296.10M
Bulls Say, Bears Say
Bulls Say
First PROTAC Approval And Strategic ValidationVEPPANU’s approval validates Arvinas’s targeted protein degradation platform and establishes a regulatory precedent for PROTAC medicines. The Rigel out-license also demonstrates external commercial interest, creating potential milestone, royalty, and partnership value beyond the current pipeline.
Strong Balance Sheet And Extended RunwaySubstantial liquidity and minimal leverage give Arvinas flexibility to fund clinical development without immediate dependence on debt or equity markets. Runway into H2 2028 supports continued investment through multiple data readouts and provides time to pursue partnerships or approvals.
Broad Pipeline With Differentiated BiologyThe pipeline spans oncology and neurology and includes evidence that degradation may achieve biological effects beyond conventional inhibition. Multiple programs and upcoming clinical transitions diversify scientific opportunity, while differentiated biomarkers can strengthen partnering and development prospects.
Bears Say
Persistent Operating Cash BurnDeeply negative operating and free cash flow show that reported profitability has not yet translated into self-funded operations. Continued development spending will consume liquidity, increasing reliance on milestones, partnerships, or future financing if programs take longer to generate durable revenue.
Revenue Is Heavily Dependent On One-time EventsRecent revenue strength does not establish a recurring commercial base because much of it came from accounting recognition, upfront payments, and milestones. Future results may therefore remain volatile, and the absence of recurring product revenue leaves earnings dependent on collaboration progress.
Clinical Execution And Regulatory Timing RiskSlower enrollment, sub-efficacious early ARV-393 cohorts, and the ARV-102 postponement delay evidence needed to validate important assets. These issues can extend development timelines, defer potential partnering or milestone opportunities, and increase cash consumption before clinical uncertainty declines.
Arvinas Holding Company News
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $6.74 and its highest was $14.51 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $474.70M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Nov 10, 2026 which is in 19 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on Aug 04, 2026. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of -$0.374 by $2.954.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -0.87.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 65,386,190 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of $2.58 in its last earnings report, beating expectations of -$0.374. Following the earnings report the stock price went up 11.663%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arvinas Holding Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.07 (56.96% Upside)
$15.07 (56.96% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 46.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.19%
12-Months-Change
Fundamentals
Return on Equity
1.91%
Trailing 12-Months
Asset Growth
-25.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Arvinas Holding Company
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
ARVN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized major strategic and scientific milestones — notably the first PROTAC approval (VEPPANU), substantial one-time revenue recognition and continued advancement of multiple clinical and preclinical programs with clear near-term data catalysts. Arvinas has strengthened focus on Phase I oncology and neurology assets, reported meaningful cost reductions and maintained a cash runway into H2 2028. Offsetting these positives are execution and timing challenges: ARV-393 enrollment was slowed by conservative starting doses (yielding mostly sub-efficacious cohort data in 2026), ARV-102 experienced regulatory delays pushing patient trials into 2027, cash declined ~17% YoY, and recent revenue was materially driven by one-time licensing and milestone events. Overall, the call leans positive because substantive strategic wins, upcoming clinical catalysts and a solid balance sheet (despite the cash decline) outweigh the program-specific delays and one-time accounting impacts.View all ARVN earnings summariesARVN Stock 12 Month Forecast
Average Price Target
$15.07
▲(56.96% Upside)
Technical Analysis
MacroGenics
―
Zentalis Pharmaceuticals
―
Prelude Therapeutics
―
C4 Therapeutics
―
Olema Pharmaceuticals
―
Ownership Overview
3.62% Insiders
19.04% Mutual Funds
0.37% Other Institutional Investors
62.09% Public Companies and
Individual Investors